Biến nạp tạm thời trong nuôi cấy tế bào HEK 293 không có huyết tương để sản xuất hiệu quả rFVIII người

Grillberger L, Kreil TR, Nasr S, Reiter M: Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnology Journal. 2009, 4: 186-201. 10.1002/biot.200800241. Lynch CM, Israel DI, Kaufman RJ, Miller AD: Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther. 1993, 4: 259-272. 10.1089/hum.1993.4.3-259. Kolind MP, Norby PL, Flintegaard TV, Berchtold MW, Johnsen LB: The B-domain of factor VIII reduces cell membrane attachment to host cells under serum free conditions. Journal of Biotechnology. 2010, 147: 198-204. 10.1016/j.jbiotec.2010.04.010. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, Gangadharan B, Parker ET, Lollar P, Doering CB: Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII. Molecular Therapy. 2011, 19: 302-309. 10.1038/mt.2010.239. Dorner AJ, Bole DG, Kaufman RJ: The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol. 1987, 105: 2665-2674. 10.1083/jcb.105.6.2665. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ: Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989, 9: 1233-1242. Kaufman RJ: Expression and structure-function properties of recombinant factor VIII. Transfusion Medicine Reviews. 1992, 6: 235-246. 10.1016/S0887-7963(92)70174-6. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 1997, 8 (Suppl 2): S3-14. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004, 103: 3412-3419. 10.1182/blood-2003-10-3591. Lynch TJ: Biotechnology: alternatives to human plasma-derived therapeutic proteins. Baillieres's Clinical Haematology. 2000, 13: 669-688. Garber K: rFactor VIII deficit questioned. Nature Biotechnology. 2000, 18: 1133-10.1038/81098. Pham PL, Perret S, Doan HC, Cass B, St-Laurent G, Kamen A, Durocher Y: Large-scale transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng. 2003, 84: 332-342. 10.1002/bit.10774. Pham PL, Kamen A, Durocher Y: Large scale transfection of mammalian cells for the fast production of recombinant protein. Molecular Biotechnology. 2006, 34: 225-237. 10.1385/MB:34:2:225. Côté J, Garnier A, Massie B, Kamen A: Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng. 1998, 59: 567-575. 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8. Tonn T, Herder C, Becker S, Seifried E, Grez M: Generation and Characterization of Human Hematopoietic Cell Lines Expressing Factor VIII. Journal of Hematotherapy & Stem Cell Research. 2002, 11 (4): 695-704. 10.1089/15258160260194848. Tom R, Bisson L, Durocher Y: Transient expression in HEK293-EBNA1 cells. Methods Express: Expression Systems. Edited by: Dyson MR, Durocher Y. 2007, Oxfordshire: Scion Publishing Ltd, 203-223. Sun X, Hia HC, Goh PE, Yap GS: High-density transient gene expression in suspension-adapted 293 EBNA1 cells. Biotechnology and Bioengineering. 2008, 99: 108-116. 10.1002/bit.21537. Durocher Y, Perret S, Kamen A: High-level and hogh-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002, 30: E9-10.1093/nar/30.2.e9. Ansorge S, Lanthier S, Transfiguracion J, Durocher Y, Henry O, Kamen A: Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J Gene Med. 2009, 11: 868-76. 10.1002/jgm.1370. Adamson R: Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol. 1994, 68 (Suppl 3): S9-14. Winge S: Method for isolation of recombinantly produced proteins. 2006, International Application No.: PCT/EP2006/061148. Pub. No.: WO/2006/103258 Sunley K, Butler M: Strategies for the enhancement of recombinant protein production from mammalian cells by growth arrest. Biotechnology Advances. 2010, 28: 385-394. 10.1016/j.biotechadv.2010.02.003. Rieder CL, Cole RW: Cold shock and the mammalian cell cycle. Cell Cycle. 2002, 1: 169-175. Yoon SK, Song JY, Lee GM: Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol Bioeng. 2003, 82: 289-98. 10.1002/bit.10566. Jorjani P, Ozturk SS: Effects of cell density and temperature on oxygen consumption rate for different mammalian cell lines. Biotechnol Bioeng. 1999, 64: 349-356. 10.1002/(SICI)1097-0290(19990805)64:3<349::AID-BIT11>3.0.CO;2-V. Rodriguez J, Spearman M, Huzel N, Butler M: Enhanced production of monomeric interferon-β by CHO cells through the control of culture conditions. Biotechnology Progress. 2005, 21: 22-30. Oguchi S, Saito H, Tsukahara M, Tsumura H: pH Condition in temperature shift cultivation enhances cell longevity and specific hMab productivity in CHO culture. Cytotechnology. 2006, 52: 199-207. Yoon SK, Choi SL, Song JY, Lee GM: Effect of culture pH on erythropoietin production by Chinese hamster ovary cells grown in suspension at 32.5 and 37.0 degrees C. Biotechnol Bioeng. 2005, 89: 345-56. 10.1002/bit.20353. Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD, Mather JP, Etcheverry T, Ryll T: Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch cultures. Cytotechnology. 1997, 23: 47-54. 10.1023/A:1007919921991. Sakurai T, Itoh K, Liu Y, Higashitsuji H, Sumitomo Y, Sakamaki K, Fujita J: Low temperature protects mammalian cells from apoptosis initiated by various stimuli in vitro. Exp Cell Res. 2005, 309: 264-72. 10.1016/j.yexcr.2005.06.002. Ahn M-H, Song M, Oh E-Y, Jamal A, Kim H, Ko K, Choo Y-K, Kim B-J, Ko K: Production of therapeutic proteins with baculovirus expression system in insect cell. Entomological Research. 2008, 38: S71-S78. Haack A, Schmitt C, Poller W, Oldenburg J, Hanfland P, Brackmann HH, Schwaab R: Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines. Annals of Hematology. 1998, 78: 111-116. Chen C, Fang XD, Zhu J, Wu XF, Zhang ZC, Gu JX, Wang ZY, Chi CW: The Gene Expression of Coagulation Factor VIII in Mammalian Cell Lines. Thrombosis Research. 1999, 95: 105-115. 10.1016/S0049-3848(99)00031-6. Cho MS, Yee H, Brown C, Mei B, Mirenda C, Chan S: Versatile expression system for rapid and stable production of recombinant proteins. Biotechnology Progress. 2003, 19: 229-232. 10.1021/bp0255964. Mei B, Chen Y, Chen J, Pan CQ, Murphy JE: Expression of human coagulation factor VIII in a human hybrid cell line, HKB11. Molecular Biotechnology. 2006, 34: 165-178. 10.1385/MB:34:2:165. Campos-da-Paz M, Costa CS, Quilici LS, Simões IC, Kyaw CM, Maranhão AQ, Brigido MM: Production of Recombinant Human Factor VIII in Different Cell Lines and the Effect of Human XBP1 Co-Expression. Molecular Biotechnology. 2008, 39: 155-158. 10.1007/s12033-008-9055-6. Picanco-Castro V, Russo-Carbolante EMS, Fontes AM, Fernandes AC, Covas DT: An enhancer/promoter combination strengthens the expression of blood-coagulation factor VIII in non-viral expression vectors. Genetics and Molecular Research. 2008, 7: 314-325. 10.4238/vol7-2gmr447. Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J: Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thrombosis and Haemostasis. 2005, 93: 1061-1068. Lillicrap D: Extending half-life in coagulation factors: where do we stand?. Thrombosis Research. 2008, 122: S2-S8. Wakabayashi H, Varfaj F, DeAngelis J, Fay PJ: Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Hemostasis, Thrombosis, and Vascular Biology. 2008, 112: 2761-2769. Roy S, Shirley S, Connelly S, Andrews JL, Kayda DB, Gardner JM, Kaleko M: In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector. Haemophilia. 1999, 5: 340-348. 10.1046/j.1365-2516.1999.00310.x. Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem HP, Ganser A, Scherr M: Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Therapy. 2003, 10: 1917-1925. 10.1038/sj.gt.3302093. Herder C, Tonn T, Oostendorp R, Becker S, Keller U, Peschel C, Grez M, Seifried E: Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003, 23: 2266-2272. 10.1161/01.ATV.0000100403.78731.9F. Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D: Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007, 25: 2660-2669. 10.1634/stemcells.2006-0699. Kasuda S, Kubos A, Sakurai Y, Irion S, Ohashi K, Tatsumi K, Nakajiwa Y, Saito Y, Hatake K, Pipe SW, Shima M, Yoshioka A: Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A. Journal of Thrombosis and Haemostasis. 2008, 6: 1352-1359. 10.1111/j.1538-7836.2008.03022.x. Baldi L, Hacker DL, Adam M, Wurm FM: Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett. 2007, 29: 677-684. 10.1007/s10529-006-9297-y. Rozkov A, Larsson B, Gillstrom S, Bjornestedt R, Schmidt SR: Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture. Biotechnology and Bioengineering. 2008, 99: 557-566. 10.1002/bit.21603. Wright JL, Jordan M, Wurm FM: Transfection of partially purified plasmid DNA for high level transient protein expression in HEK293-EBNA cells. Journal of Biotechnology. 2003, 102: 211-221. 10.1016/S0168-1656(03)00032-4. Cheng L, Sun X, Yi X, Zhang Y: Large-scale plasmid preparation for transient gene expression. Biotechnology Letters. 2011, 33: 1559-1564. 10.1007/s10529-011-0612-x. Schorr J, Moritz P, Breul A, Scheef M: Production of plasmid DNA in industrial quantities according to cGMP guidelines. Methods Mol Med. 2006, 127: 339-50. Geisse S: Reflections on more than 10 years of TGE approaches. Protein Expression and Purification. 2009, 64: 99-107. 10.1016/j.pep.2008.10.017.